NCT06628921View on ClinicalTrials.gov

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study): a TACHIS Sub-study

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Migraine
Interventions
DRUG

Eptinezumab 100 or 300 mg ev

Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.

All Listed Sponsors
collaborator

Società Italiana per lo Studio delle Cefalee

OTHER

collaborator

Fondazione Policlinico Universitario Campus Bio-Medico

OTHER

collaborator

Azienda Ospedaliero Universitaria Policlinico Modena

OTHER

collaborator

SISC RICe Group

UNKNOWN

lead

University of Florence

OTHER

NCT06628921 - The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study): a TACHIS Sub-study | Biotech Hunter | Biotech Hunter